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Summary
One of the major challenges in chemical synthesis is
the selective oxyfunctionalization of non-activated
C-H bonds, which can be enabled by biocatalysis
using cytochrome P450 monooxygenases. In this
study, we report on the characterization of the versa-
tile CYP109Q5 from Chondromyces apiculatus
DSM436, which is able to functionalize a wide range
of substrates (terpenes, steroids and drugs), includ-
ing the ring of b-ionone in non-allylic positions. The
crystal structure of CYP109Q5 revealed ﬂexibility
within the active site pocket that permitted the
accommodation of bulky substrates, and enabled a
structure-guided approach to engineering the
enzyme. Some variants of CYP109Q5 displayed a
switch in selectivity towards the non-allylic positions
of b-ionone, allowing the simultaneous production of
2- and 3-hydroxy-b-ionone, which are chemically
challenging to synthesize and are important precur-
sors for carotenoid synthesis. An efﬁcient whole-cell
system ﬁnally enabled the production of up to
0.5 g l1 hydroxylated products of b-ionone; this sys-
tem can be applied to product identiﬁcation in fur-
ther biotransformations. Overall, CYP109Q5 proved
to be highly evolvable and active. The studies in this
work demonstrate that, using rational mutagenesis,
the highly versatile CYP109Q5 generalist can be
progressively evolved to be an industrially valuable
specialist for the synthesis of speciﬁc products.
Introduction
In modern oxidative biocatalysis, the enzyme class of
cytochrome P450 monooxygenases (P450s) represents
an environmentally friendly alternative to chemical syn-
thesis, which often proceeds under harsh reaction condi-
tions and with limited selectivity (Urlacher and Girhard,
2012). With more than 5000 cloned members, P450s
represent a large enzyme superfamily that can be found
in all kingdoms of life (Nelson, 2011). The ability to inte-
grate molecular oxygen selectively into non-activated
carbon–hydrogen bonds under mild reaction conditions
(RT, atmospheric pressure) makes P450 monooxyge-
nases especially attractive for applications in chemical
syntheses (Breuer et al., 2004; Urlacher and Girhard,
2012). In nature, P450s play a crucial role in cell meta-
bolism, for example, in terpenoid biosynthesis. Here, ter-
pene molecules are functionalized by P450s, thereby
creating a greater diversity in the organisms (Janocha
et al., 2015). Through the variability of evolved P450
enzymes (over 50 000 sequences), nature provides
strategies to oxyfunctionalize speciﬁc terpene molecules
that can be further improved for implementation into nat-
ural or synthetic pathways. However, plant or fungal
P450s are often difﬁcult to express, and often possess
low activities, thus an increasing number of microbial
enzymes are necessary to expand the P450 toolbox in
terpene chemistry (Urlacher and Schmid, 2006).
In recent times, numerous concepts have been devel-
oped in order to identify new biocatalysts with desirable
properties (Bornscheuer et al., 2012; Davids et al., 2013).
The classical strategy is to search for organisms that can
already catalyse the desired reaction, either to identify the
responsible enzymes for heterologous expression or to
adapt the organism to better performance by strain engi-
neering. Furthermore, the number of available P450
sequences that are involved in diverse metabolic path-
ways is increasing due to the rapid sequencing of gen-
omes (Urlacher and Girhard, 2012). Metagenomic
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libraries can also be exploited to rapidly display a wide
variety of different naturally occurring enzymes to screen
for desired properties (Cook et al., 2016). The constant
progress in gene synthesis technology accelerates this
strategy, since codon-optimized variants of the genes are
thus readily available for many expression systems. Par-
ticularly promising, however, is a combination of this con-
cept with the classical search among organisms in order
to identify wild-type enzymes. Organisms with special sec-
ondary metabolism, such as the myxobacterium
Sorangium cellulosum So ce56, can serve as interesting
sources for P450 monooxygenases (Shimkets et al.,
2006; Schneiker et al., 2007; Khatri et al., 2011b). Based
on already characterized P450s, the search for homolo-
gous enzymes in databases may also lead to a more tar-
geted metagenome analysis. Closely related P450s with
an amino acid sequence identity > 40% can be grouped
into families and often possess similar functions due to
their high conservation in the active site (Scheps et al.,
2011). In addition to new biocatalysts, protein engineering
provides opportunities to extend the application spectrum
of previously known P450s to modify enzyme properties
such as selectivity, activity or substrate speciﬁcity (White-
house et al., 2012; Hoffmann et al., 2016).
Terpenes represent a large, versatile class of natural
products whose structural diversity undergoes further
diversiﬁcation by the incorporation of functionalities such
as oxyfunctionalization. In recent years, research
attempted to ﬁnd bacterial P450 enzymes for the produc-
tion of such terpenoids for the ﬂavour and fragrance
industry (Daviet and Schalk, 2010). However, despite
this, the functionalization of terpenes like sesquiterpenes
(premnaspirodiene or bisabolene), or the non-allylic
hydroxylation of the ionone ring of norisoprenoids like
b-ionone, which would lead to high-value products such
as 3-hydroxy-b-ionone, b-bisabolol or the antifungal phy-
toalexin solavetivone, is rarely or not yet realized. The
extension of the putative biocatalyst spectrum to access
valuable or even novel terpenoids is thus highly desired
in the ﬂavour and fragrance industry.
In this study, we aimed to enlarge the set of P450 bio-
catalysts for terpene oxyfunctionalization. Here, we
report on the identiﬁcation, expression, biochemical and
structural characterization as well as enzyme engineer-
ing of CYP109Q5 from the myxobacterium Chon-
dromyces apiculatus DSM436. This enzyme was able to
functionalize a diverse set of substrates ranging from
monoterpenes over sesquiterpenes to steroids. By
applying enzyme engineering based on the crystal struc-
ture of CYP109Q5, regioselectivity was shifted towards
to the rarely observed non-allylic oxyfunctionalization of
b-ionone. Finally, an efﬁcient whole-cell system was
developed, to give access to the hydroxylated b-ionone
products.
Results
Identiﬁcation, expression and puriﬁcation of CYP109Q5
Myxobacteria such as S. cellulosum have already been
described as a source of a vast variety of different
P450s, some of which exhibit activities towards ter-
penes. Therefore, we searched for myxobacteria related
to S. cellulosum for which the genome sequences had
been determined. Hereby, we chose Chondromyces apic-
ulatus DSM436, which harbours 25 putative and yet
uncharacterized P450s, suggesting excellent potential
for enzyme discovery (Sharma et al., 2018). In particular,
one P450, attributed to the CYP109 family, was of inter-
est because related P450s have been shown to hydrox-
ylate terpenes (Table S1). C. apiculatus DSM436 was
obtained from the DSMZ (DSM14612) and the genomic
DNA isolated from cells grown on a VY/2 agar plate.
The gene of CYP109Q5 was ampliﬁed by corresponding
primers using PCR, puriﬁed on agarose gel and cloned
using restriction sites into pET-28a(+). A more abundant
stop codon for E. coli was also integrated with the aid of
the ampliﬁcation primers. However, only minor amounts
of functional P450 could be expressed using E. coli
BL21(DE3) or Rosetta(DE3). Accordingly, the genes
were cloned into the alternative expression vectors
pCWori(+) and pBAD33 to examine the expression.
Finally, despite the high GC content and the numerous
rare codons in the gene, high expression of 1.33 lM
(cell culture) functional P450 could be achieved for
CYP109Q5 using the pBAD33 vector in E. coli JW5510.
For the following characterization, negatively charged
CYP109Q5 was partially puriﬁed via anion exchange
chromatography with a sodium chloride step gradient
since no puriﬁcation tag was present and subsequently
analysed by SDS-PAGE (Figs. S1 and S2). CO differen-
tial spectroscopy of the reduced protein revealed a typi-
cal Soret band at 450 nm of the sodium dithionate
reduced P450 and a slight maximum at 420 nm belong-
ing to non-correctly folded CYP109Q5 (Fig. S2). The
usage of the arabinose-inducible pBAD system has thus
enabled sufﬁcient expression of functional CYP109Q5
which opened the possibility of further investigations.
Reconstitution of P450 activity and determination of
substrate spectrum
First tests were carried out in vitro using three puriﬁed
heterologous redox partner systems, CamA and CamB
from Pseudomonas putida, FdR and FdX from E. coli
JM109, or FdR in combination with AdX (bos taurus) to
increase the probability of successful activity reconstitu-
tion. Since the already characterized CYP109 members
are able to oxyfunctionalize b-ionone, valencene and
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fatty acids, we focused on these substrates to ﬁnd a
functional combination with the redox partners. Interest-
ingly, b-ionone and valencene were hydroxylated when
electrons were delivered by CamA/CamB from P. putida,
while only slight or no activity was observed with the
combinations FdR/FdX and FdR/AdX respectively.
Therefore, CamA/CamB was used to investigate the
substrate spectrum of CYP109Q5 (Fig. 1). In addition to
different norisoprenoids, both, cyclic and acyclic
monoterpenes, such as geranylacetone or limonene
were hydroxylated by the enzyme. In addition,
CYP109Q5 was able to hydroxylate cis-stilbene and
ibuprofen, as well as a variety of sesquiterpenes such
as a-humulene or b-bisabolene. CYP109Q5 also exhib-
ited activities towards diclofenac, mefenamic acid, neroli-
dol, camphor as well as the steroids progesterone and
testosterone. The hydroxylation of fatty acids as charac-
teristic of the CYP109 family was only achieved in traces
with CYP109Q5 (Table S2). Overall, CYP109Q5 has
thus shown to accept a broad spectrum of substrates
with different functionalities and size.
Structure of CYP109Q5
In order to prepare protein for X-ray crystallographic
studies, the gene encoding CYP109Q5 was codon-opti-
mized for expression in E. coli and purchased from Gen-
Script already ligated into pET-28a(+), equipping the
protein with an N-terminal histidine tag. The gene was
expressed in E. coli BL21(DE3) and puriﬁed using nickel
afﬁnity and gel ﬁltration chromatography. Crystals of
CYP109Q5 diffracted to 1.55 A and were in the P211
space group, with one monomer in the asymmetric unit.
Data collection and reﬁnement statistics can be found in
Table S3. The polypeptide chain was complete except
for a region G165 to A175, constituting the ‘FG loop’,
Fig. 1. Substrate spectrum of CYP109Q5 from C. apiculatus DSM436. In vitro biotransformations were performed with puriﬁed P450 (2 lM)
and CamA and CamB as the redox partners for 24 h. Conversions were estimated based on the product areas relative to the internal standard
carvone. 1: b-ionone; 2: vinylionol; 3: b-damascone; 4: a-ionone; 5: pseudoionone; 6: nootkatone; 7: geranylacetone; 8: nerol; 9: linalool; 10:
limonene; 11: a-terpineol; 12: carvone; 13: thujene; 14: b-caryophylleneoxide; 15: b-caryophyllene; 16: camphor; 17: a-humulene; 18: longi-
folene; 19: b-bisabolene; 20: premnaspirodiene; 21: valencene; 22: nerolidol; 23: zerumbone; 24: ibuprofen; 25: cis-stilbene; 26: diclofenac; 27:
mefenamic acid; 28: testosterone; 29: progesterone.
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which could not be modelled presumably to its mobility
(Fig. 2). The structure of CYP109Q5 was observed to
adopt the classical P450 fold, and analysis using the
DALI server (Holm and Laakso, 2016) suggested that
the closest structural homologue was a vitamin D3 25-
hydroxylase from Pseudonocardia autotrophica (PDB
code 5GNL), with 36% sequence identity, and giving an
rmsd of 1.5 A over 362 C-a atoms. The major difference
between the two enzyme structures was an extended
loop between N58 and P77, which, in CYP109Q5, has
folded up to meet the G-helix, possibly restricting access
to the haem (Fig. 2). The active site cavity is large and
hydrophobic, with I232 and A236 at one side of the
haem, and W61 and V80 brought to the other side of the
substrate access channel by the movement of the N58-
P77 loop. V80 corresponds to F87 in P450 BM3, which
plays a crucial role in the determination of activity and
selectivity (Whitehouse et al., 2012). However, the posi-
tion of W61, whose indole N atom is in contact with the
haem propionate, is not a core element in the P450
superfamily and is thus special to the CYP109Q5 struc-
ture. The residue A280 is also part of the active site that
is the ﬁfth amino acid after the conserved ExxR motif the
alteration of which also showed great inﬂuence on the
enzyme properties (Seifert and Pleiss, 2009). In addition,
a big cavity could be seen in the surface display which
presumably enables the accommodation of bulky and/or
long acyclic substrates (Fig. S3). Finally, the high-resolu-
tion structure enabled us to precisely alter the enzyme
properties by rational enzyme engineering.
Rational enzyme engineering of CYP109Q5
By the use of CYP109Q5 from C. apiculatus DSM436, a
diverse set of substrates such as terpenes as well as
many other important compounds could be converted.
More interestingly, besides the allylic 4-hydroxy-b-
ionone, two further products with m/z of 208 correspond-
ing to putative hydroxylation or epoxidation products
were observed in the biotransformation with b-ionone as
substrate. At this point, the approach of rational enzyme
engineering was of great interest to inﬂuence the activity
and selectivity positively for enabling determination of
the exact structures. Furthermore, we also wanted to
determine whether we can inﬂuence oxyfunctionalization
of the sesquiterpenes. For this purpose, the crystal struc-
ture of CYP109Q5 was analysed using a P450-3DM
database, and additionally, b-ionone, as well as prem-
naspirodiene, was modelled into the active site using
AutoDock VINA implemented in YASARA Structure
(Trott and Olson, 2010). The result exhibiting the highest
binding energy of 8.50 kcal mol1 for b-ionone and
7.93 kcal mol1 for premnaspirodiene is shown in Fig. 3.
Based on the analysis on hotspot regions in P450
enzymes and the contact to the docked substrates using
the database, amino acid residues were selected for
semirational mutagenesis (Fig. 3, right). In particular,
hydrophobic amino acids of different sizes were chosen
for mutation. The database also provided information
about which amino acid distribution exists in the entire
P450 superfamily at a speciﬁc position. A focused align-
ment (subset) with terpene-hydroxylating P450s was fur-
ther used to determine amino acids occurring at the
corresponding position. Besides V80, I232, A233 and
A280, further amino acids close to the catalytically active
haem were also addressed (T237, I283 and T229). In
total, 28 single variants were ﬁnally generated by the
QuikChange method using the pBAD33 construct carry-
ing the native CYP109Q5 gene. All variants were
heterologously expressed in E. coli strain JW5510 and
tested for 24 h in vitro using cell lysate of the respective
P450 variant with CamA/CamB as redox partners. The
results with selected terpenes were analysed and the
effect of the exchange determined based on the product
peak areas relative to the internal standard (Table S4,
Fig. S4). As already observed with the wild-type enzyme,
several products were detected over a reaction time of
24 h, the distribution of which sometimes differed
Fig. 2. Crystal structure of CYP109Q5. The monomer as well as a comparison with the vitamin D3 25-hydroxylase from Pseudonocardia
autotrophica (PDB code 5GNL, grey) is shown with the haem in orange. The main difference in both structures is the movement of the
N58-P77 loop in CYP109Q5 (blue) bringing W61 and V80 to the substrate access channel.
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signiﬁcantly from that of the wild-type. Overall, the
respective variant showed similar effects such as an
increased activity with the different terpenes. Substitu-
tions with the most impact on activity and/or selectivity
after mutagenesis were V80G/A, T229S/L, T237S,
A280I/V and I283L. The substitution of position V80
resulted in a strong effect on activity and selectivity.
While the small hydrophobic amino acids glycine and
alanine caused partial increase in activity with most of
the terpenes, the activity decreased considerably over
leucine to isoleucine compared to the wild-type (valine).
The mutations T229L and T229S had a positive inﬂu-
ence on activity and led to the largest change of product
distribution in comparison with all variants. This could be
observed especially with the norisoprenoids b-ionone
and vinylionol. In the P450 3DM-superfamily (~38 000
sequences), 85% of the proteins exhibit a threonine at
position 237, which is associated with O2 activation
(Aikens and Sligar, 1994; Gober et al., 2016). Threonine
was therefore substituted by serine (6% of proteins),
which had a positive effect on activity and selectivity.
Investigating the inﬂuence of hydrophobic residues of
varying size, hotspot position A280 was substituted cor-
respondingly. While mutating A280 to leucine and
phenylalanine resulted in a negative effect on the activity
of CYP109Q5, A280I and A280V showed a strong
increase in activity with a concomitant change in product
distribution with most of the substrates. A similar positive
effect could be achieved with the mutagenesis of posi-
tion I283, in particular with the variant I283L. Since these
exchanges are mostly located on the opposite side of
the active pocket (Fig. 3), we investigated the combina-
tions of the most promising variants focusing on the
positions V80 and A280, thereby generating ten double
variants the effects of which were analysed similar to the
single variants (Table S4). All the double variants, com-
bining V80G or V80A and ﬁve replacements at position
A280, had strong positive inﬂuences on the activity and
selectivity of CYP109Q5. Furthermore, increased activi-
ties were achieved with the double variants V80G/I283L
and V80G/T237S respectively. However, these variants
showed low functional expression, characterized by a
strong maximum at 420 nm in the CO difference spec-
trum (data not shown). For the double variants V80G/
T229S and V80G/T229L, respectively, no actively folded
P450 was obtained after expression. By contrast, the
combination A280V/T229L could be well expressed and
showed a strong positive effect on activity and selectivity
compared to the wild-type.
In vitro characterization using partially puriﬁed enzyme
For detailed in vitro characterization, eight variants show-
ing the greatest effects in terms of activity and selectivity
compared to the wild-type were selected. In total, four sin-
gle variants (V80, A280I, A280V and I283L) and four dou-
ble variants (V80A/A280I, V80A/A280L, V80G/A280I and
A280V/T229L) were successfully partially puriﬁed by
anion exchange chromatography and their concentration
and functionality determined by CO difference spec-
troscopy (Table S5). The biotransformations with the par-
tially puriﬁed variants and the wild-type were carried out
for 2 h in vitro with CamA/CamB as redox partners with
selected substrates (Fig. 4 and S4). For comparison,
CYP109B1 from B. subtilis was also used, because the
products of the biotransformations using this enzyme with
b-ionone and valencene as substrates are known (Girhard
et al., 2010). Although puriﬁcation and reduction of the
reaction time reduced the by-product formation to a small
extent, many different products and other oxidations were
detected, which were ﬁnally analysed by GC-FID and
GC-MS. Using b-ionone as a substrate, similar activities
were achieved with the different variants (Fig. 4). The
wild-type formed 0.75  0.04 mM of hydroxylated prod-
ucts using 1 mM of b-ionone after 2 h reaction time. Inter-
estingly, with some variants, shifts in product distribution
from the allylic product towards two further oxyfunctional-
ized products (m/z 208) were obtained conﬁrming the pre-
vious lysate screenings. Using the variants, products such
as P3 (A280I) as well as shifts to the product P4 (A280V/
Fig. 3. Strategy of the rational enzyme design of CYP109Q5. The substrates b-ionone (blue, left) and premnaspirodiene (blue, right) were mod-
elled in the active pocket using the AutoDock Vina algorithm implemented in YASARA. Right: The surfaces of the amino acids for mutagenesis
are shown in green which were selected based on literature data (3DM-database) and contacts to the ligands.
ª 2018 The Authors. Microbial Biotechnology published by John Wiley & Sons Ltd and Society for Applied Microbiology., Microbial
Biotechnology, 12, 377–391
Characterization and engineering of CYP109Q5 381
T229L) could be achieved. Similar shifts were observed
with the other norisoprenoids such as vinylionol or
b-damascone as substrates (Fig. S5). With the substrate
premnaspirodiene, an approximately threefold increase in
activity could be obtained with the variants A280I and
V80A/A280I compared to the wild-type. Both variants also
catalysed further oxidation to multiple oxyfunctionalized
products (m/z 234). With the variants, the ratios of P2, P4
and P5 shifted rather than that new products were formed.
The greatest increase in activity was measured with
valencene as substrate (Fig. S5). An increase of up to ten
times was achieved with variant V80A/A280I, which
mainly showed further oxidation products of nootkatone.
In biotransformations with possible products such as
nootkatone and caryophyllene oxide, activity was gener-
ally higher than that of the similar non-oxyfunctionalized
compounds a-humulene and valencene. In addition, other
compounds such as diclofenac, mefenamic acid and aro-
madendrene were also tested and in some cases, high
increase in activity, especially with the V80A/A280I vari-
ant, was observed (Fig. S5). With diclofenac, ibuprofen
and mefenamic acid, respectively, 40-hydroxydiclofenac,
2-hydroxyibuprofen and 30-hydroxymethylmefenamic acid,
respectively, were selectively formed using all variants. In
total, high impact on selectivity and/or activity of the stud-
ied variants could be demonstrated compared to the
CYP109Q5 wild-type.
CYP109Q5 whole-cell biocatalyst
Since for most of the terpenes no product standards are
available, the identiﬁcation of the products turned out to
be difﬁcult. First indications were obtained using GC-MS
analysis, but these do not allow the exact structure
Fig. 4. CYP109Q5 in vitro product formation and distribution using b-ionone (A and C) and premnaspirodiene (B and D) as substrates. The
CYP109Q5 wild-type, selected variants and in case of b-ionone CYP109B1 from B. subtilis were tested as puriﬁed enzymes with CamA and
CamB as redox partners. Biotransformations were performed with 2 lM puriﬁed P450 and 1 mM substrate for 2 h and analysed by GC-FID
and GC-MS. For the quantiﬁcation of the products, 0.2 mM carvone was used as internal standard. A threshold value of 0.07 (area product
divided by area of internal standard) was deﬁned for each product and total product formation was normalized on the wild-type CYP109Q5.
Following values of area product divided by area internal standard were reached with the puriﬁed wild-type enzyme: 4.25 (b-ionone); 0.44
(premnaspirodiene).
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elucidation. In order to generate sufﬁcient product titres
for solving the structure of unknown products, we con-
structed a dual-vector system consisting of pBAD33 car-
rying the P450 and the compatible pBAD18 vector
including CamA/CamB, each under the same arabinose-
inducible promoter system in E. coli JW5510. The best
result with the highest activity per cell was ﬁnally
obtained by induction with 0.1% (v/v) L-arabinose and
expression at 25°C overnight (Fig. S6). The experiments
with CYP109Q5 were performed in vivo after expression
in the dual-vector system with resting cells. High activi-
ties were achieved when b-ionone from a DMSO stock
was used as substrate. For characterization of the prod-
ucts, the preparative biotransformations were carried out
with the CYP109Q5 variant A280V/T229L, which
showed high activity in vitro with a simultaneous shift of
the product spectrum towards the previously unknown
hydroxylated products (Fig. 4). In total, 0.5 g l1 of the
oxyfunctionalized products were generated in the prepar-
ative biotransformations in 100 ml scale after 24 h.
Semipreparative HPLC puriﬁcation allowed the isolation
of all three products efﬁciently for NMR analysis
(Fig. S7). The main product (74%) was the allylically
hydroxylated 4-hydroxy-b-ionone. The second product
peak (7%) in the GC-FID or ﬁrst in the semipreparative
HPLC turned out to be 3-hydroxy-b-ionone. Furthermore,
2-hydroxy-b-ionone was identiﬁed as a third product.
Also hydroxylated in non-allylic position, it was formed
as 19% proportion of the product mixture. In contrast to
the in vitro reactions, the whole-cell system ﬁnally pro-
duced sufﬁcient amounts for the structure elucidation.
Discussion
In this work, we focused on the identiﬁcation and further
development of new P450 biocatalysts for the oxyfunc-
tionalization of different terpenes. While many examples
exist for the allylic hydroxylation of b-ionone and the
hydroxylation of valencene, so far only a few P450s are
known capable of accepting more bulky sesquiterpene
candidates of the terpene spectrum (Janocha et al.,
2015). Instead of specialists, we were looking for gener-
alists who can be used in manyfold ways in the fra-
grance and ﬂavour industry. Depending on future
application, biocatalysts can ﬁnally be transformed into a
specialist with speciﬁc properties by protein engineering
(Bornscheuer et al., 2012; Otte and Hauer, 2015). P450s
from a family or subfamily show often similar substrate
spectra. For the identiﬁcation of novel terpene hydroxy-
lases, we therefore searched for organisms that possess
large numbers of potentially interesting P450s for the
oxyfunctionalization of terpenes. Studies on the
myxobacterium S. cellulosum So ce56 have already
identiﬁed and characterized P450s, able to efﬁciently
hydroxylate norisoprenoids and sesquiterpenes
(Ly et al., 2012; Schifrin et al., 2015; Litzenburger and
Bernhardt, 2016). Myxobacteria feature the largest bac-
terial genomes known today and a versatile secondary
metabolism, making them particularly interesting for
biotechnological applications (Schneiker et al., 2007;
Diez et al., 2012). With C. apiculatus, a related
myxobacterium, the P450s of which have not yet been
investigated, was selected. Use of the strictly regulated
pBAD33 expression vector was the key factor for the
production of CYP109Q5 from C. apiculatus DSM436. It
turned out that the activity reconstitution was enabled
using CamA/CamB as heterologous redox partners
which are thus suitable to supply electrons to multiple
P450s (Bell et al., 2010; Reisky et al., 2018). The
enzyme displayed a wide range of catalysed reactions
from diverse norisoprenoids, steroids, non-steroidal anti-
inﬂammatory drugs to mono- and sesquiterpenes
(Fig. 1). Interestingly, CYP109Q5 showed only minimal
activity with fatty acids, which distinguishes this enzyme
from the CYP109 members that are actually declared as
fatty acid hydroxylases, such as CYP109B1, CYP109C1,
CYP109C2 or CYP109D1 (Girhard et al., 2010; Khatri
et al., 2013). The amino acid sequence identity of this
novel C. apiculatus enzyme is 39% to CYP109B1, 44%
to CYP109C1, 43% to CYP109C2 and 38% to
CYP109D1. Studies on the steroid hydroxylating
CYP109E1 from B. megaterium (36% identity to
CYP109Q5) showed that this enzyme is more closely
related to the steroid hydroxylase CYP106A1 in compar-
ison with the already characterized CYP109 enzymes
(Jozwik et al., 2016). Classiﬁcation into a P450 family
thus represents a strong evidence for a particular sub-
strate spectrum; this is reﬂected by CYP109B1 and
CYP109E1 that also functionalize a broad spectrum of
substrates including steroids, fatty acids and terpenes
(Girhard et al., 2010; Putkaradze et al., 2017). However,
the preferences or natural substrates may differ in large
and heterogeneous P450 families such as the CYP109
family.
A combined strategy of substrate docking, comparison
with other terpene hydroxylases, and mutational data
from the literature was used for rational enzyme design.
At the same time, the focus was set on two important
positions in P450s (V80 and A280), which should have a
decisive inﬂuence on activity and selectivity. In particular,
the substitutions at positions V80, T229, I283 and A280
showed a large positive inﬂuence on the activity and
changed the product spectrum, while partly even an
additive effect was detectable. Position 57 in the 3DM
database (V80 in CYP109Q5) as well as the position ﬁve
amino acid residues after the conserved ExxR motif
(A280) points towards the haem. It can be assumed that
these residues interact with all substrates, resulting in a
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high inﬂuence on the activity and selectivity. The posi-
tions I283 and T229 are further away from the catalyti-
cally active haem iron, nevertheless also in direct
contact with the substrates, presumably affecting selec-
tivity. As crucial position for orienting the substrates for
regioselective oxidation, T229 was identiﬁed as equiva-
lent position to human CYP2A6 (N297; Di et al., 2009).
Finally, eight variants were selected, partially puriﬁed
and further characterized in vitro (Fig. 3 and S4). The
reference CYP109B1 hydroxylated b-ionone exclusively
in the allylic position, while with the wild-type and vari-
ants of CYP109Q5 two further hydroxylated by-products
could be identiﬁed. Hereby, the pBAD33/pBAD18
expression system proved to be extremely effective. The
in vivo product formation of 0.5 g l1 using CYP109Q5
A280V/T229L was far superior to that of similar systems,
such as the P450s from S. cellulosum with titres in the
lower mg l1 range (Khatri et al., 2011a; Litzenburger
and Bernhardt, 2016). Compared to the most active
b-ionone-biocatalyst known today, CYP101B1
(0.83 g l1), this is only a slightly lower titre (Hall and
Bell, 2015). The ratio of the products was equivalent to
that of the in vitro biotransformations. This ﬁnally allowed
the puriﬁcation and structure elucidation of the by-pro-
ducts formed by the CYP109Q5 variant A280V/T229L.
Interestingly, in addition to the allylic oxidized main pro-
duct, these two main by-products were found to be
hydroxylated in non-allylic positions of the ionone ring
(Fig. 5). With CYP101B1 and C1 from Novosphingob-
ium aromaticivorans and CYP264B1 from S. cellulosum
as exceptions (Bell et al., 2010; Ly et al., 2012), P450s
usually hydroxylate in an allylic position (Table S6). Even
excessive mutational studies with P450 BM3 have failed
to yield any variants showing activity in the non-allylic
position of norisoprenoids (Eiben et al., 2006; Urlacher
et al., 2006; Venkataraman et al., 2012). The reason for
this is the reactivity of the positions in the ionone ring.
The regioselectivity is mainly controlled by the bond dis-
sociation energy and the steric accessibility. The two
methyl groups on the ionone ring direct the oxidation to
the more sterically accessible C3. The electronic activa-
tion of the allylic C-H bond (low dissociation energy) by
the double bond on the ionone ring ﬁnally leads to an
oxidation of the energetically favoured C4 position (Khur-
san et al., 1997; Gossauer, 2006; Janocha et al., 2015).
The oxyfunctionalization of the C2 and C3 positions on
the ionone ring by CYP109Q5 thus represents a spe-
cialty. For the ﬁrst time, the functionalization of all three
positions was achieved, the product distribution of which
could be shifted especially with the variants A280I and
A280V/T229L by mutagenesis. While the A280V/T229L
double variant formed 21% 2-hydroxy-b-ionone and 7%
3-hydroxy-b-ionone in vitro, variant A280I produced 6%
and 29% respectively (Fig. 5). A possible explanation for
the observed activities and shifts can be found in the
crystal structure of CYP109Q5 modelled with b-ionone
(Fig. 6). While CYP109Q5 has a very large active site
pocket that can also accommodate steroids, for exam-
ple, the crystal structure of CYP101C1 from N. aromati-
civorans cocrystallized with b-ionone reveals binding
with low degree of freedom. This enzyme is able to
hydroxylate b-ionone in allylic and C3 position at a ratio
of 75 to 25 (Bell et al., 2010). The activity can be
rationalized by the crystal structure in which the C4 posi-
tion of the ionone ring is closest to the active haem iron
(Fig. 6, top left). In contrast, the docking experiments
with CYP109Q5 indicate a possible orientation of the C2
and C3 positions of b-ionone to the haem (Fig. 6, top
right). Accordingly, there appears to be enough space in
the active pocket for the functional bonding of all three
positions, which may explain the formation of a mixture
of all three hydroxylated products. Considering further
the mutagenesis-modiﬁed conformation of the A280V/
T229L double variant, it can be seen that both positions
have a decisive inﬂuence on the orientation of b-ionone
in front of the catalytically active haem (Fig. 6, bottom
left and right). Similar product shifts were also observed
with other norisoprenoids, which is why the production of
non-allylic oxyfunctionalized products is also likely here.
The active pocket can be modelled accordingly to favour
selectivity for a particular product and there are many
more interesting positions like W61, combinations, posi-
tions in the substrate access channel or loops which
might have a high impact on enzyme properties.
With respect to the other terpenes, some variants led
in vitro to enormous increases in product formation
(Fig. 4 and S4). At the same time, in comparison with
the wild-type, new or even multiple oxyfunctionalized
products were formed using the most active variants. Ini-
tially, this gave the impression that the selectivity was
reduced by mutagenesis. However, it was found that
some products were increasingly formed due to higher
activity compared to detected product traces with the
wild-type. Molecular masses of 220 or 234 also suggest
Fig. 5. CYP109Q5-catalysed oxyfunctionalization of b-ionone. The
in vitro product distribution is presented for the wild-type and a
selection of variants. The products 2-hydroxy-, 3-hydroxy- and
4-hydroxy-b-ionone were identiﬁed by NMR spectroscopy.
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alcohol overoxidation to the corresponding ketone or
aldehyde presumably catalysed by the P450 via a
gem-diol; such activity has already been described in
previous work (Sowden et al., 2005). In fact, the formed
products seem to be better substrates than the original
substrates, which can be explained, inter alia, by
increased water solubility and reactivity through the ﬁrst
oxyfunctionalization. This is corroborated by a higher
activity towards the potential product nootkatone
(Fig. S5).
There are only few examples for biocatalysts with activ-
ity towards the tested sesquiterpenes such as a-humu-
lene, b-bisabolene or premnaspirodiene, which makes the
enzyme CYP109Q5 particularly interesting. The previous
examples for the production of 5- or 8-hydroxy-a-humu-
lene were extended by the biocatalyst identiﬁed in this
work (Yu et al., 2011; Schifrin et al., 2015). For the ﬁrst
time, oxyfunctionalization of b-bisabolene was enabled by
a heterologously expressed bacterial P450. Considering
the hydroxylation of premnaspirodiene, so far only one
example for a biocatalyst is known in the literature (Taka-
hashi et al., 2007). Since multiple oxyfunctionalized prod-
ucts of premnaspirodiene with m/z 220 and 218 were
obtained in vitro (Fig. 4, down), the formation of highly
desired solavetivol and the further oxidized solavetivone
(m/z 218) are likely. This is corroborated by the docking
experiment showing the highest binding energy with a
premnaspirodiene conformation that favours hydroxylation
to solavetivol (Fig. 3, right). The in vivo generated prod-
ucts using CYP109Q5 are thus of particular interest for
future applications.
Overall, CYP109Q5 has emerged as a universally
applicable biocatalyst for the oxyfunctionalization of a
broad range of norisoprenoids, sesquiterpenes and other
compounds. Based on the developed whole-cell system,
production of industrially relevant products using this
enzyme must be evaluated in future work. Furthermore,
completely new products are conceivable the properties
of which can be investigated by the CYP109Q5-cata-
lysed synthesis. Once these products have been identi-
ﬁed, tailor-made specialists can be designed based on
the crystal structure and the outstanding evolvability of
the enzyme. The ability to oxidize non-activated C-H
bonds, as in the case of b-ionone, makes CYP109Q5
particularly interesting for industrial processes and pro-
vides an excellent starting point for further investigation.
Fig. 6. Comparison of active pockets of CYP101C1 from N. aromaticivorans and CYP109Q5 from C. apiculatus. In the case of the CYP109Q5
crystal structure, the substrate b-ionone (blue) was bound into the active pocket using AutoDock Vina. Top, left: CYP101C1 cocrystallized with
b-ionone, PDB ﬁle: 3OFU; Top, right: crystal structure of CYP109Q5 wild-type with b-ionone; Bottom, left: lateral view of the active site of the
wild-type CYP109Q5; Bottom, right: lateral view of the active pocket of the CYP109Q5 variant A280V/T229L with the two docking results (blue
and yellow) exhibiting the highest binding energy. In silico mutagenesis was performed by YASARA and the structure was subsequently energy
minimized.
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Since even very large and bulky substrates such as pro-
gesterone are effectively oxyfunctionalized, evaluating
di- and triterpenes as substrates is the next logical step
which may enlarge the versatility of CYP109Q5 for future
applications.
Experimental procedures
Cloning of CYP109Q5
The isolation of the genomic DNA from Chondromyces
apiculatus DSM436 was carried out directly from a VY/2
agar plate. The cells were scraped off and resuspended
in ddH2O. The recovery of the DNA was ﬁnally carried
out with the Gene JET Genomic DNA Puriﬁcation Kit
(Thermo Fisher Scientiﬁc Inc., Waltham, MA, USA) and
elution with 200 ll ddH2O. The gene of CYP109Q5
(EYF04172) was ampliﬁed by PCR using the KOD HS
DNA polymerase (Novagene Inc., Madison, WI, USA).
Appropriate primers were designed to introduce a NdeI
as well as a HindIII restriction site on the 30-fragment
end. Thereby, a more frequently used stop codon from
E. coli was introduced. After PCR ampliﬁcation, the frag-
ment was subsequently subcloned into the pET-28a(+)
vector behind the poly-histidine-tag through the corre-
sponding restriction sites. The gene was further sub-
cloned into pCWori+ and pBAD33 using the NdeI and
HindIII restriction sites. DNA sequencing (GATC Biotech
AG, Konstanz, Germany) veriﬁed the correct constructs.
The sequences of the primers and the PCR procedure
are given in Tables S7 and S8.
Expression and puriﬁcation
The heterologous protein expression in E. coli was car-
ried out in 400 ml of TB medium containing the corre-
sponding antibiotic in 2 l bafﬂed ﬂasks. A 3 ml overnight
culture from a fresh transformation plate was used for
inoculation, and the cultivation was continued at 37°C
and 100 rpm until a OD600 of 1.5–1.8 was reached. Sub-
sequently, the cultures were slowly cooled to the expres-
sion temperature and induced as listed in Table S9 to
start protein expression. The expression was prolonged
for 15 h at 100 rpm. After harvesting the cells for 15 min
at 6000 g and 4°C, the pellets were frozen at 20°C
until further processing. Cells containing a protein with a
poly-histidine-tag (CamA, CamB and FdR) were resus-
pended to 0.25 gcww ml
1 in cold immobilized metal
afﬁnity chromatography (IMAC) buffer (50 mM KPi
pH 7.0, 150 mM NaCl, 10% glycerol). Cold ion exchange
chromatography (IEX) buffer (A: 50 mM KPi pH 7.5,
0.5% glycerol or B: 50 mM Tris/HCl pH 8.2 (25°C), 0.5%
glycerol) was used to resuspend cells to 0.25 gcww ml
1
which expressed proteins for the puriﬁcation via IEX
(CYP109Q5, AdX, FdX). 0.1 mM PMSF was freshly
added and the cell suspensions were sonicated (Bran-
son Soniﬁer 250 equipped with a microtip: 3 mm diame-
ter; Danbury, CT, USA) for 4 min on ice (pulse: Output
3–5, Duty cycle: 35%). Cell lysate was obtained by cen-
trifugation at 55 000 g for 30 min at 4°C, and the super-
natant was subsequently ﬁltered over a 0.45 lm
membrane ﬁlter. The N-terminally poly-histidine-tagged
proteins were puriﬁed by IMAC. Therefore, the ﬁltered
cell lysate was loaded on a His GraviTrap Talon resin
(1 ml column volume ≙ cv; GE Healthcare, Freiburg,
Germany) pre-equilibrated with 8 cv IMAC buffer. After
binding to the cobalt packed column, non-speciﬁcally
bound proteins were eluted with 5 cv IMAC buffer
(10 mM imidazole) followed by 5 cv buffer containing
20 mM imidazole. The target proteins were eluted
through 8 cv IMAC buffer with 150 mM imidazole. After
that, the eluates containing the desired proteins were
dialysed against 5 l ice-cold IMAC buffer overnight (max.
30 ml eluate) to ensure removal of imidazole. If needed,
the puriﬁed proteins were further concentrated by Vivas-
pin20 columns (cut-off 10 kDa; Sartorius, Goettingen,
Germany). For IEX, the columns Toyopearl DEAE 650M
XK16/40 30 ml cv and GigaCap DEAE 650M XK50/20
90 ml cv (both Tosoh Bioscience, Griesheim, Germany)
were applied on a €AKTApuriﬁer 10 system equipped with
an Frac-950 fraction collector (GE Healthcare). After
1 cv equilibration (buffer B), the lysate containing
CYP109Q5 was loaded onto the GigaCap DEAE 650M
column and washed with 2 cv of buffer B. A two-step
gradient (70 mM NaCl for 1 cv, 300 mM NaCl for
1.75 cv) was used to elute the target protein. The super-
natants containing AdX and FdX in IEX buffer A were
loaded on the 30 ml DEAE 650M resin equilibrated with
3 cv IEX buffer A. The column was washed with 2 cv of the
same buffer before elution of bound proteins with a linear
gradient of 0–1 M NaCl developed over 10 cv. Elution was
followed by UV using A420 for CYP109Q5 or the speciﬁc
absorption maxima of the redox proteins shown below.
Fractions with the highest target protein to A280 ratio were
combined and the buffer exchanged through Vivaspin20
columns (cut-off 10 kDa) to the IMAC buffer while concen-
trating the samples. Finally, the IMAC and IEX puriﬁed pro-
teins were aliquoted to 200 ll and stored at 20°C until
use. The P450 concentrations were determined by CO dif-
ference spectroscopy according to the method of Omura
and Sato using e450-490 = 91 mM
1 cm1 (1964). Protein
concentration of the redox partners was determined as fol-
lows: CamA (average of 378, 454 and 480 nm; (e) 9.7, 10.0
and 8.5 mM1 cm1); CamB (average of 415 and 455 nm;
(e) 11.1 and 10.4 mM1 cm1); FdR (456 nm; (e)
7.1 mM1 cm1); FdX (464 nm; (e) 8.42 mM1 cm1);
AdX (414 nm; (e) 11.0 mM1 cm1; Huang and Kimura,
1973; Fujii and Huennekens, 1974; McIver et al., 1998;
Purdy et al., 2004).
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Crystallization of CYP109Q5
A gene encoding CYP109Q5, codon-optimized for expres-
sion in E. coli, was purchased from GenScript, already
ligated into a pET-28a(+) plasmid. The construct con-
tained an N-terminal histidine tag to achieve higher puri-
ties for crystallization. Following transformation of E. coli
BL21(DE3) cells, a single colony was used to inoculate a
10 ml culture in LB broth containing 30 lg ml1 kanamy-
cin, which was grown overnight with shaking at 37°C.
10 ml of the overnight culture was then used to inoculate
500 ml of TB containing 30 lg ml1 kanamycin. This lar-
ger culture was grown at 37°C with shaking until the
OD600 reached a value of 1.0. The culture was then
induced with 0.4 mM IPTG and supplemented with
0.2 mM FeSO4 and 0.5 mM 5-Ala. Expression was con-
ducted overnight at 18°C with shaking. Cells were har-
vested by centrifugation at 5000 g for 30 min. The pellets
were resuspended in a buffer containing 50 mM K2HPO4,
300 mM KCl and 30 mM imidazole at pH 7.0, with 0.1 mM
PMSF. The cells were ruptured using a French press at
40 kPsi. The lysate was centrifuged at 50 000 g for
45 min at 4°C. The soluble fraction was loaded onto a
HisTrap FF column (GE Healthcare) pre-equilibrated with
the buffer and eluted with an increasing gradient of imida-
zole. Fractions were analysed by SDS-PAGE and those
deemed to contain CYP109Q5 were pooled, concentrated
to a volume of 500 ll, and loaded onto a size exclusion
column (Hiload 16/60 Superdex 200 PrepGrade; GE
Healthcare) pre-equilibrated with a buffer containing
50 mM Tris and 300 mM NaCl at pH 7.5. Fractions were
again analysed by SDS-PAGE and those deemed to con-
tain CYP109Q5 of the best purity were pooled and con-
centrated using Vivaspin20 columns (cut-off 10 kDa) for
crystallization trials (Fig. S8).
CYP109Q5 was crystallized using high-purity protein
samples of concentration equal to 15 mg ml1. INDEX
and PACT screens were set up using a Mosquito
robot (TTP Labtech, Melbourn, UK) in MRC plates
using sitting drop method. CYP109Q5 crystals were
grown in conditions containing 0.2 M NaCl, 0.1 M Tris
pH 8.5 and 28% (w/v) PEG3350. The most promising
crystals were ﬂash-cooled in liquid nitrogen using 10%
glycerol in the mother liquor as cryoprotectant, and
retained for analysis at the synchrotron.
Data collection and reﬁnement
A complete data set for CYP109Q5 was collected at the
Diamond Light Source, Didcot, Oxfordshire, U.K., on
beamline I04. The data were processed and integrated
using XDS (Kabsch, 2010) and scaled using SCALA
(Evans, 2006) within the Xia2 processing software
(Winter, 2010). Data collection statistics are given in
Table S3. Crystals of CYP109Q5 were in space group
P211. The structure was solved using MOLREP (Vagin
and Teplyakov, 1997), using CYP109A2 (5OFQ, Abdul-
mughni et al., 2017) from Bacillus megaterium as the
search model. The solution contained one monomer in the
asymmetric unit and the solvent content was 42.4%. The
structure was built and reﬁned using iterative cycles using
Coot (Emsley and Cowtan, 2004) and REFMAC (Murshu-
dov et al., 1997), employing local NCS restraints. The ﬁnal
structure had Rcryst and Rfree values of 18.5% and 22.0%.
Reﬁnement statistics are presented in Table S3. The
Ramachandran plot showed 97.3% of residues in allowed
regions, 2.4% in preferred regions and 0.3% in outlier
regions. Coordinate ﬁles and structure factors have been
deposited in the Protein Data Bank (PDB) with the coordi-
nate accession number 6GMF.
Molecular docking and rational design
Molecular docking of b-ionone and premnaspirodiene into
the P450 active pocket was performed using the Auto-
Dock Vina algorithm implemented in YASARA (Trott and
Olson, 2010). The water molecules inside the active site
and the channel were removed before for the docking
experiment. In silico mutagenesis were applied by the
swap tool in YASARA and subsequent energy minimiza-
tion of the protein structure. Structural alignment with
5GNL was performed using the YASARA MUSTANG
module. The rational design was conducted by site-direc-
ted mutagenesis using the QuikChange method as
described in the Supporting information (Table S10).
In vitro biotransformations
The in vitro reactions were carried out in a volume of
200 ll in reaction buffer (50 mM KPi pH 7.0, 150 mM
NaCl, 2.5% glycerol). The glucose 6-phosphate dehydro-
genase system (G6PDH from L. mesenteroides) was
used to regenerate the cofactor NAD(P)H (12 U ml1
G6PDH, 5 mM G6P, 1 mM MgCl2). Standard in vitro reac-
tions contained 100 lg ml1 catalase, 2 mM NAD(P)H
and 1 mM substrate (50 mM stock solution in DMSO or
ethanol, all tested substrates are listed in Table S2). All
components were mixed, and the biotransformation was
started with the addition of a mixture of P450 (lysate or
puriﬁed), reductase, ﬂavodoxin or ferredoxin in the stoi-
chiometric ratio 1:1.5:15 (2 lM:3 lM:30 lM). The reac-
tions were incubated for 2–24 h at 30°C and 180 rpm and
subsequently prepared for analysis. Negative controls
were either lysates generated by the expression of the
empty vector, or in the case of reactions with partially puri-
ﬁed P450s, all reaction components except the P450.
ª 2018 The Authors. Microbial Biotechnology published by John Wiley & Sons Ltd and Society for Applied Microbiology., Microbial
Biotechnology, 12, 377–391
Characterization and engineering of CYP109Q5 387
Construction of a whole-cell system
The dual-vector system was created based on the com-
patible pBAD18 and pBAD33 vectors. The plasmid
pBAD18_CamB_CamA was constructed via Gibson
Assembly using the speciﬁc primers listed in Table S7.
The fragments (vectors and inserts) ampliﬁed through
PCR (Table S11) were controlled by an agarose gel and
isolated using the ZymocleanTM Gel DNA Recovery Kit
(Zymo Research Corp., Irvine, CA, USA) for puriﬁcation.
Gibson Assembly was ﬁnally performed with 15 ll Gib-
son Assembly mix and 5 ll DNA mix [vector to insert(s),
molar ratio 1:5, total ~300 ng] for 1 h at 50°C. After trans-
formation in chemically competent E. coli XL1-blue cells,
isolated plasmid constructs were checked for correct mod-
iﬁcation by DNA sequencing. For expression, the pBAD18
plasmid encoding the redox partners was transformed in
competent E. coli JW5510 cells and new chemical compe-
tent cells prepared thereof. As next step, pBAD33 encod-
ing the CYP109Q5 gene was freshly transformed each
time prior expression. Expression of the three proteins
was conducted in 400 ml of TB medium containing the
corresponding antibiotic in 2 l bafﬂed ﬂasks. A 3 ml over-
night culture from a fresh transformation plate was used
for inoculation and the cultivation was continued at 37°C
and 100 rpm until a OD600 of 1.5–1.8 was reached. Sub-
sequently, the cultures were slowly cooled to 25°C and
induced with 0.1% L-arabinose, 0.5 mM FeSO4 and
0.5 mM 5-Ala to start protein expression. The expression
was prolonged for 15 h at 100 rpm. After protein expres-
sion, the cells were harvested for 15 min at 6000 g and
4°C and the resulting pellets directly resuspended with
100 mM KPi pH 7.0 supplemented with 30 mM glucose
(to 0.2 gcww ml
1).
Preparative in vivo biotransformations
The resting cell reactions were performed in 500 ml baf-
ﬂed shaking ﬂasks with a reaction volume of 100 ml, a
ﬁnal cell concentration of 0.1 gcww ml
1, with 30 mM glu-
cose and with 5 mM b-ionone (250 mM stock solution in
DMSO) for 24 h at 30°C and 180 rpm. A 750 ll sample
was taken of each reaction for GC analysis. The prod-
ucts were puriﬁed using reverse phase semipreparative
HPLC and structurally elucidated by 1H-, 1H-COSY- and
13C-NMR spectra as described in the Supporting infor-
mation (Figs. S9–S11).
Product analysis
The in vitro (200 ll) or in vivo (supernatant: 750 ll) sam-
ples were extracted with the same volume MTBE con-
taining 0.2 mM carvone as internal standard. In case of
a necessary derivatization of the analytes, acidiﬁcation
of the samples by 10 ll (in vitro) was performed before
these were extracted with MTBE (including 0.3 mM 3-
methoxyphenylacetic acid as internal standard). Before
derivatization, the organic phase was evaporated on a
Genevac EZ-2 Plus Evaporator (SP Scientiﬁc, Ipswich,
UK) to dryness and the residual dissolved in a 90 ll mix-
ture of 50% MTBE and 50% BSTFA + TMCS (99:1).
Derivatization of the samples was carried out in GC vials
for 30 min at 70°C. Gas chromatography was performed
on a Shimadzu GC-2010 equipped with an AOC-20i
autoinjector (Shimadzu, Nakagyo-ku, Japan). The sam-
ples were injected with different split ratios (injector tem-
perature 250°C, carrier gas H2, 30 cm s1) and
separated via a DB-5 or HP-1 ms-ui column (both 30 m
9 0.25 mm 9 0.25 lm; Agilent Technologies Inc., Santa
Clara, CA, USA). The analytes were detected by means
of a ﬂame ionization detector (FID, detector temperature
330°C) using the programs listed in Table S12. For initial
product identiﬁcation, the samples were afterwards anal-
ysed on a Shimadzu GCMS-QP2010 detector using the
identical temperature programs. In case of the non-ster-
oidal anti-inﬂammatory drugs, product standards were
available from a previous study using microbial biocata-
lysts (Klenk et al., 2018). HPLC measurements of
diclofenac were performed as described elsewhere
(Klenk et al., 2017). An Agilent 1260 HPLC (Agilent)
equipped with single quad ESI-MS was used for the
LCMS analysis of the steroids testosterone and proges-
terone. The chromatographic separation of 10 ll sample
was ensured with a Supelco C18 discovery column
(150 9 4.0 mm, 5 lm; from Sigma-Aldrich, St Louis,
MO, USA). An isocratic gradient of 60% MeOH and 40%
H2O + 0.1% v/v formic acid was used for 20 min at a
ﬂow rate of 1 ml min1 at 30°C and a detection wave-
length of 244 nm. MS parameters: ESI ionization; scan
m/z 80–400; drying gas temperature 350°C; drying gas
ﬂow 9.0 l min1; nebulizer pressure 35 psi; Vcap
+3000 V; fragmentation voltage 70 eV. The sample
preparation was performed by extraction with the same
volume of MTBE (200 ll), evaporation of the organic
phase on a Genevac EZ-2 Plus Evaporator and uptake
of the residues in 150 ll of the mobile phase. Examples
of GC, HPLC and LCMS chromatograms are given in
Figures S12–S16.
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